TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Clinical Performance of the Guardian Laryngeal Mask With LMA Proseal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:• Ambulatory patients scheduled to undergo knee arthroscopy, transurethral resection of bladder tumor, hand, gynecological and general surgical under a short general paralysed anesthesia of less than 2 hours (American Society of Anesthesiologists physical status I-II)~* 18 to 65 years of age~* Mallampati score less than 3~* thyromental distance more than 6.5 cm~* mouth opening more than \>2.5 cm~* a body mass index less than 35 kg/m2;~Exclusion Criteria:~* Body weight 50 Kg~* Pregnancy~* Difficult airway~* Recent history of upper respiratory tract infection and sore throats~* A history of esophageal reflux disease~* ENT surgery~* Laparoscopic surgery~* Inability to understand the Study Information Sheet and provide a written consent to take part in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Guardian (Type: EXPERIMENTAL): Device: Guardian Laryngeal Mask
- Proseal (Type: EXPERIMENTAL): Device:Proseal Laryngeal Mask Airway

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Core Inclusion Criteria:~* Histologically confirmed PD-L1 status defined NSCLC. Biopsy must be within 70 days of first treatment with pembrolizumab.~* ECOG performance status 2.~* Life expectancy \> 12 weeks.~* Uni-dimensionally measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1~* Computerised Tomography (CT) scan of chest and abdomen within 28 days of starting pembrolizumab.~* Adequate haematological function:~  * Platelet count ≥100 x 109 /L.~ * Neutrophils ≥1.5 x 109/L.~ * Haemoglobin ≥ 90 g/L.~* Adequate hepatic function:~  * Serum bilirubin ≤1.5 x upper limit of normal (ULN).~ * Serum transaminases ≤2.5 x ULN.~* Adequate renal function: Creatinine clearance \<1.5 times ULN concurrent with creatinine clearance \>50 ml/min.~* Provision of signed and dated, written informed consent prior to any trial specific procedures, sampling and analyses.~Core Exclusion Criteria:~* Patients who do not meet the criteria of performance status = 2 on the ECOG Performance scale.~* Untreated symptomatic brain or leptomeningeal metastatic disease.~* Medical or psychiatric conditions compromising informed consent.~* Any medical condition which in the opinion of the investigator would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.~* Radiotherapy within 28 days of trial treatment.~* Active autoimmune disease that has required systemic treatment in past 2 years~* Chronic usage of steroids or other immunosuppressant medication.~* Previous history of pneumonitis.~* Any evidence of clinical autoimmunity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab (Type: EXPERIMENTAL): Pembrolizumab: 200 mg Q3W, intravenous administration for a maximum of 2 years, or until progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Noradrenalin vs Terlipressin in Hepatorenal Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatorenal syndrome~* Age: 18-75 years~* Informed written consent~Exclusion Criteria:~* Multinodular hepatocellular carcinoma (more than 3 nodules)~* Portal vein thrombosis~* Ongoing bacterial infection~* Ongoing or recent (less than one week) bleeding~* Cardio-pulmonary failure~* Coronary artery disease~* Peripheral artery disease~* Arterial hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Terlipressin
- 1 (Type: EXPERIMENTAL): Noradrenalin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria: Healthy infants between 5 and 10 weeks of age at first study vaccination with (after the 2002 RV season) confirmed negative HIV status of the subject's mother during pregnancy or thereafter. Exclusion criteria: History of allergic disease, any confirmed or suspected immunosuppressive or immunodeficient condition, clinically significant history of chronic gastrointestinal disease or other serious medical condition as determined by the investigator or had not received treatment prohibited by the protocol.

- Gender: ALL
- Minimum Age: 5 Weeks
- Maximum Age: 10 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Development of Ivermectin for Alcohol Use Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 21 and 65;~* meet current DSM-V diagnostic criteria for an alcohol use disorder~Exclusion Criteria:~* current treatment for alcohol problems, a history of treatment in the 30 days before enrollment or current treatment seeking;~* a current (last 12 months) DSM-V diagnosis of dependence on any psychoactive substances other than alcohol and nicotine;~* a lifetime DSM-IV diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder;~* positive urine screen for narcotics, amphetamines, or sedative hypnotics;~* serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-R);~* pregnancy, nursing, or refusal to use reliable method of birth control (if female);~* a medical condition that may interfere with safe study participation (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes);~* AST, ALT, or GGT ≥ 3 times upper normal limit;~* currently on prescription medication that contraindicates use of IVN;~* any other circumstances that, in the opinion of the investigators, compromises participant safety.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ivermectin (Type: EXPERIMENTAL): Ivermectin 30 mg single dose
- Sugar pill (Type: PLACEBO_COMPARATOR): Matched placebo, single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Arginine as a Treatment for Sickle Cell Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of H SS or S-beta thalassemia~* History of at least one vaso-occlusive pain event in the 12 months prior to study entry~* Regular compliance with comprehensive medical care~* In a steady disease state and not in the midst of any acute complication due to SCD at study entry~Exclusion Criteria:~* Inability to take or tolerate oral medications~* Liver dysfunction (i.e., SGPT level greater than or equal to two times the normal limit and albumin level less than or equal to 3.2 g/dL)~* Kidney dysfunction ( i.e., creatinine level greater than or equal to 1.2 mg/dL for children and greater than or equal to 1.4 mg/dL for adults)~* Allergy to arginine~* Pregnant~* Received a blood transfusion within the 90 days prior to study entry~* More than 10 hospital admissions for pain in the 12 months prior to study entry~* Daily use of opioids and experiencing unstable pain that interferes with work or daily routine~* Required more than 3 hospital admissions and more than 10 emergency department/day hospital visits in the 12 months prior to study entry~* Received treatment with hydroxyurea within the 90 days prior to study entry~* Received treatment with any investigational drug in the 90 days prior to study entry

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: ACTIVE_COMPARATOR): 0.05 g/kg/day Arginine
- High Dose (Type: ACTIVE_COMPARATOR): 0.10 g/kg/day Arginine
- Placebo (Type: PLACEBO_COMPARATOR): No Arginine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients require histological biopsy and paraffin block more than 5mg from the original tumour or metastatic site to perform EGFR mutational analysis~* WHO Performance Status 0-2~* No prior chemotherapy, biological or immunological therapy/surgery~Exclusion Criteria:~* Any evidence of clinically active interstitial lung disease~* Newly diagnosed CNS metastases that have not yet been definitively treated with surgery /radiation~* Patients with previously diagnosed and treated CNS metastases or spinal cord compression

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gefitinib (Type: EXPERIMENTAL): Gefitinib 250mg tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (males and females) \>16 years old with a diagnosis of ITP, a pl count \<30x109/L AND a clinical need for first line treatment.~* Patients have provided written informed consent~Exclusion Criteria:~* The exclusion criteria include pregnancy and breastfeeding~* Patients with HIV, Hepatitis B or C, or Common Variable immunodeficiency.~* Women of child bearing potential require a pregnancy test result within 7 days prior to randomisation (as per 7.1 below) to rule out unintended pregnancy~* Contraindications to MMF or steroid (see SPC, Appendix 2) including patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients or active significant infection~* Patients not capable of giving informed consent (e.g. due to incapacity)~* Patients unwilling to follow contraceptive advice if allocated to MMF treatment arm.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Steroid & Mycophenolate mofetil 1st line (Type: EXPERIMENTAL): Mycophenolate mofetil: 1 gm bd Non-IMP Steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
- Prednisolone (Steroid) alone 1st line (Type: ACTIVE_COMPARATOR): Non-IMP steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lopinavir/Ritonavir Monotherapy in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV infected children ages 2 to 18 years~2. Treated with double boosted PIs during the last three months~3. Two consecutive plasma HIV-RNA levels \< 50 copies/ml at least 3 months apart~4. Willing to restart HAART with the same regimen as before enrollment, when indicated~5. Signed written informed consent~Exclusion Criteria:~1. Active AIDS-defining disease at screening~2. Pregnancy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Children who have completed HIV-NAT 017. Children treated with other double boosted PIs such as indinavir plus lopinavir/ ritonavir are also included.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be healthy boys or girls, 11-17 years of age~* Must be a virgin with no intention of becoming sexually active during the study period~* Must have been properly vaccinated against diphtheria, tetanus, pertussis and polio~Exclusion Criteria:~* Must not have received a vaccine against diphtheria, tetanus, pertussis and polio in the past 5 years~* Must not have received any prior human papillomavirus (HPV) vaccine

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Concomitant/CMF
- Group 2 (Type: EXPERIMENTAL): Non-Concomitant/CMF
- Group 3 (Type: EXPERIMENTAL): Concomitant/FMF
- Group 4 (Type: EXPERIMENTAL): Non-Concomitant/FMF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal or negative urine pregnancy test if female~* No fever on the day of vaccination~Exclusion Criteria:~* History of allergy to vaccine components~* History of pneumococcal disease~* Received any live virus vaccination within 4 weeks prior to study start~* Received any inactivated vaccination within 7 days prior to study start~* Received any blood products within 5 months prior to study start~* Participated in an investigational drug or vaccine study in the past 30 days~* Received immunosuppressive therapy~* Patient has an immune deficiency

- Gender: ALL
- Minimum Age: 59 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1st Revaccination Group (Type: EXPERIMENTAL): None
- 2nd Revaccination Group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of MPS 7 based on leukocyte or fibroblast glucuronidase enzyme assay, or genetic testing.~2. Under 5 years of age at the time of informed consent.~3. Written informed consent of Legally Authorized Representative after the nature of the study has been explained, and prior to any research-related procedures.~Exclusion Criteria:~1. Undergone a successful bone marrow or stem cell transplant or has evidence of any degree of detectable chimaerism with donor cells.~2. Any known hypersensitivity to rhGUS or its excipients that, in the judgment of the Investigator, places the subject at increased risk for adverse effects.~3. Use of any investigational product (drug or device or combination) other than UX003 within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments at any time during the study.~4. Has a condition of such severity and acuity, in the opinion of the Investigator, which may not allow safe study participation. For patients with hydrops fetalis, the ongoing interventions to manage fluid balance can be continued; if the addition of enzyme replacement therapy (ERT) is considered a fluid-overload risk, the individual should be excluded.~5. Has a concurrent disease or condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or affect safety. Since hydropic patients have a high rate of mortality, the risk of death prior to 1 year of age should not be considered sufficient to exclude the patient from the study for compliance.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- UX003 (Type: EXPERIMENTAL): UX003 4 mg/kg every other week (QOW). Initial treatment period 48 weeks. Continuation period up to 240 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female aged ≥20 years~2. Maintenance of dual or triple antiplatelet therapy at least 12 ± 6 months after PCI with DES~3. No history of further clinical event after PCI with DES~4. Plan to change to antiplatelet monotherapy~5. Agreement to give written informed consent~Exclusion Criteria:~1. History of hypersensitivity to aspirin or clopidogrel~2. History of contraindication to aspirin or clopidogrel~3. Active pathologic bleeding, such as peptic ulcer, tumor bleeding or intracranial hemorrhage~4. History of major bleeding, BARC class ≥3, resulting in stop of antiplatelet agents within 3 months~5. Bleeding diathesis~6. Known coagulopathy or refusal of blood transfusion~7. Presence of non-cardiac comorbidity with life expectancy \&lt;2 years from randomization~8. Plan to surgery or intervention which needs to stop antiplatelet agents ≥3 months~9. Females with childbearing potential or breast-feeding~10. Conditions that may result in protocol non-compliance by the committees~11. Co-administration of contraindicated medications as follows: other P2Y 12 inhibitors (prasugrel or ticagrelor); anticoagulants (warfarin, new oral anticoagulants, or chronic therapy of heparin); cytochrome P450 2C19 inhibitors (fluoxetine, moclobemid or voriconazole); probenecid; high dose of methotrexate (≥15 mg/week); lithium~12. Refusal to give written informed consent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): Antiplatelet monotherapy : Clopidogrel 75mg P.O. daily
- Aspirin (Type: PLACEBO_COMPARATOR): Antiplatelet monotherapy : Aspirin 100\~200mg P.O. daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete